Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Genomics
Beam Therapeutics prepares for IPO
by Ryan Cross
October 6, 2019
| A version of this story appeared in
Volume 97, Issue 39
Less than 18 months after Beam Therapeutics launched with its first round of private funding, the gene-editing start-up has filed paperwork for a $100 million initial public offering on Nasdaq. Beam is developing therapies derived from the CRISPR base editors invented in David Liu’s lab at the Broad Institute of MIT & Harvard. Liu’s editors, published in 2016, can change a single nucleotide of DNA into another nucleotide. Beam is working on 12 drug programs, with an initial focus on blood, liver, and eye diseases, as well as CAR T-cell therapies.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2025 American Chemical Society
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X